Predictive approaches for drug combination discovery in cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Drug combinations have been proposed as a promising therapeutic strategy to overcome drug resistance and improve efficacy of monotherapy regimens in cancer. This strategy aims at targeting multiple components of this complex disease. Despite the increasing number of drug combinations in use, many of them were empirically found in the clinic, and the molecular mechanisms underlying these drug combinations are often unclear. These challenges call for rational, systematic approaches for drug combination discovery. Although high-throughput screening of single-agent therapeutics has been successfully implemented, it is not feasible to test all possible drug combinations, even for a reduced subset of anticancer drugs. Hence, in vitro and in vivo screening of a large number of drug combinations are not practical. Therefore, devising computational methods to efficiently explore the space of drug combinations and to discover efficacious combinations has attracted a lot of attention from the scientific community in the past few years. Nevertheless, in the absence of consensus regarding the computational approaches used to predict efficacious drug combinations, a plethora of methods, techniques and hypotheses have been developed to date, while the research field lacks an elaborate categorization of the existing computational methods and the available data sources. In this manuscript, we review and categorize the state-of-the-art computational approaches for drug combination prediction, and elaborate on the limitations of these methods and the existing challenges. We also discuss about the recent pan-cancer drug combination data sets and their importance in revising the available methods or developing more performant approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
Yadav, B., Wennerberg, K., Aittokallio, T., & Tang, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.09.001 · Cited by 845
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769
Inconsistency in large pharmacogenomic studies
Haibe-Kains, B., El-Hachem, N., Birkbak, N. J., Jin, A. C., Beck, A. H., Aerts, H. J. W. L., & Quackenbush, J. (2013) · Nature · doi:10.1038/nature12831 · Cited by 499
Self-citationPharmacogenomic agreement between two cancer cell line data sets
The Cancer Cell Line Encyclopedia Consortium, & The Genomics of Drug Sensitivity in Cancer Consortium (2015) · Nature · doi:10.1038/nature15736 · Cited by 418
Chaft, J. E., Oxnard, G. R., Sima, C. S., Kris, M. G., Miller, V. A., & Riely, G. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1468 · Cited by 418
An unbiased oncology compound screen to identify novel combination strategies
O'Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0843 · Cited by 407
A New Bliss Independence Model to Analyze Drug Combination Data
Zhao, W., Sachsenmeier, K., Zhang, L., Sult, E., Hollingsworth, R. E., & Yang, H. (2014) · SLAS Discovery · doi:10.1177/1087057114521867 · Cited by 322
A community computational challenge to predict the activity of pairs of compounds
Community, N.-D., Bansal, M., Yang, J., Karan, C., Menden, M. P., Costello, J. C., Tang, H., Xiao, G., Li, Y., Allen, J., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3052 · Cited by 321
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Eroglu, Z., & Ribas, A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015616934 · Cited by 316
Kim, K.-T., Lee, H. W., Lee, H.-O., Song, H. J., Jeong, D. E., Shin, S., Kim, H., Shin, Y., Nam, D.-H., Jeong, B. C., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-0945-9 · Cited by 198
Interaction Index and Different Methods for Determining Drug Interaction in Combination Therapy
Lee, J. J., Kong, M., Ayers, G. D., & Lotan, R. (2007) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400701199593 · Cited by 135
Patient-derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment
Scott, C. L., Becker, M. A., Haluska, P., & Samimi, G. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00295 · Cited by 100
Research works printed but not linked: 68
- Bozic, 2013, Evolutionary dynamics of cancer in response to targeted combination therapy, Elife, 2, e00747., 10.7554/eLife.00747 · DOI · Paper page
- DeVita, 1975, Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer, Cancer, 35, 98, 10.1002/1097-0142(197501)35:1<98::AID-CNCR2820350115>3.0.CO;2-B · DOI · Paper page
- Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- Gadzicki, 2005, BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib, Cancer Genet Cytogenet, 159, 164, 10.1016/j.cancergencyto.2004.09.021 · doi:10.1016/j.cancergencyto.2004.09.021
- Lim, 2014, Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21, J Thorac Oncol, 9, 506, 10.1097/JTO.0000000000000095 · DOI
- Fisher, 2012, Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma, Cancer Manag Res, 4, 243
- Sun, 2015, Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment, Acta Pharmacol Sin, 36, 1219, 10.1038/aps.2015.92 · DOI · Paper page
- Hochhaus, 2002, Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy, Leukemia, 16, 2190, 10.1038/sj.leu.2402741 · DOI · Paper page
- Apperley, 2007, Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia, Lancet Oncol, 8, 1018, 10.1016/S1470-2045(07)70342-X · DOI · Paper page
- Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to Gefitinib or Erlotinib, PLoS Med, 2, e17., 10.1371/journal.pmed.0020017 · DOI · Paper page
- Bardelli, 2010, Molecular mechanisms of resistance to Cetuximab and Panitumumab in Colorectal cancer, J Clin Oncol, 28, 1254, 10.1200/JCO.2009.24.6116 · DOI · Paper page
- Kummar, 2010, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Nat Rev Drug Discov, 9, 843, 10.1038/nrd3216 · DOI · Paper page
- Mathews Griner, 2014, High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells, Proc Natl Acad Sci USA, 111, 2349, 10.1073/pnas.1311846111 · DOI · Paper page
- Fidock, 2004, Antimalarial drug discovery: efficacy models for compound screening, Nat Rev Drug Discov, 3, 509, 10.1038/nrd1416 · DOI · Paper page
- Demidem, 1997, Chimeric Anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B Cell Lymphoma cell line to cell killing by Cytotoxic Drugs, Cancer Biother Radiopharm, 12, 177, 10.1089/cbr.1997.12.177 · DOI · Paper page
- Gillet, 2013, The clinical relevance of cancer cell lines, J Natl Cancer Inst, 105, 452, 10.1093/jnci/djt007 · DOI · Paper page
- Hidalgo, 2014, Patient-derived xenograft models: an emerging platform for translational cancer research, Cancer Discov, 4, 998, 10.1158/2159-8290.CD-14-0001 · DOI · Paper page
- Choi, 2014, Lessons from patient-derived xenografts for better in vitro modeling of human cancer, Adv Drug Deliv Rev, 79–80, 222, 10.1016/j.addr.2014.09.009 · DOI · Paper page
- Fang, 2015, Experimental design and statistical analysis for three-drug combination studies, Stat Methods Med Res
- Zinner, 2009, Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells, Mol Cancer Ther, 8, 521, 10.1158/1535-7163.MCT-08-0937 · DOI
- Li, 2015, Large-scale exploration and analysis of drug combinations, Bioinformatics, 31, 2007, 10.1093/bioinformatics/btv080 · DOI · Paper page
- Lee, 2012, CDA: combinatorial drug discovery using transcriptional response modules, PLoS One, 7, e42573., 10.1371/journal.pone.0042573 · DOI
- Parkkinen, 2014, Probabilistic drug connectivity mapping, BMC Bioinformatics, 15, 113., 10.1186/1471-2105-15-113 · DOI
- Huang, 2014, DrugComboRanker: drug combination discovery based on target network analysis, Bioinformatics, 30, i228, 10.1093/bioinformatics/btu278 · DOI · Paper page
- Sun, 2015, Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer, Nat Commun, 6, 8481, 10.1038/ncomms9481 · DOI · Paper page
- Zhao, 2011, Prediction of drug combinations by integrating molecular and pharmacological data, PLoS Comput Biol, 7, e1002323., 10.1371/journal.pcbi.1002323 · DOI · Paper page
- Tallarida, 2006, An overview of drug combination analysis with isobolograms, J Pharmacol Exp Ther, 319, 1, 10.1124/jpet.106.104117 · DOI · Paper page
- Chou, 1977, A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems, J Biol Chem, 252, 6438, 10.1016/S0021-9258(17)39978-7 · DOI · Paper page
- Chou, 1977, On the determination of availability of ligand binding sites in steady-state systems, J Theor Biol, 65, 345, 10.1016/0022-5193(77)90329-0 · DOI
- Chou, 1976, Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands, J Theor Biol, 59, 253, 10.1016/0022-5193(76)90169-7 · DOI · Paper page
- Chou, 1974, Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition, Mol Pharmacol, 10, 235, 10.1016/S0026-895X(25)13852-2 · DOI · Paper page
- Loewe, 1953, The problem of synergism and antagonism of combined drugs, Arzneimittelforschung, 3, 285
- Nordling, 1953, A new theory on the cancer-inducing mechanism, Br J Cancer, 7, 68, 10.1038/bjc.1953.8 · DOI · Paper page
- Finney, 1952, Probit Analysis, J Am Pharm Assoc, 41, 627
- Reed, 1928, The application of the logistic function to experimental data, J Phys Chem, 33, 760, 10.1021/j150299a014 · DOI · Paper page
- Loewe, 1926, Über Kombinationswirkungen, Archiv Für Experimentelle Pathologie Und Pharmakologie, 114, 313, 10.1007/BF01952257 · DOI · Paper page
- Grindey, 1975, Approaches to the rational combination of antimetabolites for cancer chemotherapy, Drug Design, 169, 10.1016/B978-0-12-060305-3.50010-2 · DOI
- Sartorelli, 1965, Approaches to the combination chemotherapy of transplantable Neoplasms, Prog Tumor Res, 228, 10.1159/000391373 · DOI
- Venditti, 1964, Drug synergism in antineoplastic chemotherapy, Adv Chemother, 397, 10.1016/B978-1-4831-9929-0.50013-9 · DOI
- Burger, 1964, Drugs in our society, J Med Chem, 7, 835, 10.1021/jm00336a055 · doi:10.1021/jm00336a055
- Veldstra, 1956, Synergism and potentiation with special reference to the combination of structural analogues, Pharmacol Rev, 8, 339, 10.1016/S0031-6997(25)06966-2 · DOI
- Bulusu, 2016, Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives, Drug Discov Today, 21, 225, 10.1016/j.drudis.2015.09.003 · DOI · Paper page
- Ryall, 2015, Systems biology approaches for advancing the discovery of effective drug combinations, J Cheminform, 7, 7, 10.1186/s13321-015-0055-9 · DOI · Paper page
- Lopez, 2016, Combine and conquer: challenges for targeted therapy combinations in early phase trials, Nat Rev Clin Oncol
- Chou, 1983, Analysis of combined drug effects: a new look at a very old problem, Trends Pharmacol Sci, 4, 450, 10.1016/0165-6147(83)90490-X · DOI · Paper page
- Ritz, 2005, Bioassay analysis using R, J Stat Softw, 12, 1, 10.18637/jss.v012.i05 · DOI · Paper page
- Dreβler, 1999, CombiTool—a new computer program for analyzing combination experiments with biologically active agents, Comput Biomed Res, 32, 145, 10.1006/cbmr.1999.1509 · DOI
- Smirnov, 2015, PharmacoGx: an R package for analysis of large pharmacogenomic datasets, Bioinformatics, 32, 1244, 10.1093/bioinformatics/btv723 · DOI · Paper page
- Laskey, 2014, A mechanistic theory to explain the efficacy of antiretroviral therapy, Nat Rev Microbiol, 12, 772, 10.1038/nrmicro3351 · DOI
- Li, 2014, Systems pharmacology strategies for drug discovery and combination with applications to cardiovascular diseases, J Ethnopharmacol, 151, 93, 10.1016/j.jep.2013.07.001 · DOI
- Wu, 2010, A systems biology approach to identify effective cocktail drugs, BMC Syst Biol, 4(Suppl 2), S7., 10.1186/1752-0509-4-S2-S7 · DOI
- Cunningham, 2009, Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer, J Clin Oncol, 27, 5513, 10.1200/JCO.2009.24.2446 · DOI · Paper page
- Marsh, 2015, Pancreatic cancer and FOLFIRINOX: a new era and new questions, Cancer Med, 4, 853, 10.1002/cam4.433 · DOI
- Wong, 2008, Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm, Proc Natl Acad Sci USA, 105, 5105, 10.1073/pnas.0800823105 · DOI · Paper page
- Sirota, 2011, Discovery and preclinical validation of drug indications using compendia of public gene expression data, Sci Transl Med, 3, 96ra77., 10.1126/scitranslmed.3001318 · DOI · Paper page
- Harrell, 1996, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors, Stat Med, 15, 361, 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
- Wei, 2006, Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance, Cancer Cell, 10, 331, 10.1016/j.ccr.2006.09.006 · DOI · Paper page
- Forrest, 1993, Genetic algorithms: principles of natural selection applied to computation, Science, 261, 872, 10.1126/science.8346439 · DOI · Paper page
- Bartlett, 1935, Contingency table interactions, Suppl J R Stat Soc, 2, 248, 10.2307/2983639 · DOI · Paper page
- Kang, 2015, Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach, Stat Med, 34, 685, 10.1002/sim.6370 · DOI · Paper page
- Tang, 2015, What is synergy? The Saariselkä agreement revisited, Front Pharmacol, 6, 181, 10.3389/fphar.2015.00181 · DOI · Paper page
- Greco, 1992, Consensus on concepts and terminology for combined-action assessment: the Saariselkä agreement, Arch Complex Environ Stud, 4, 65
- Safikhani, 2016, Assessment of pharmacogenomic agreement, 10.12688/f1000research.8705.1 · DOI
- Haverty, 2016, Reproducible pharmacogenomic profiling of cancer cell line panels, Nature, 533, 333, 10.1038/nature17987 · DOI · Paper page
- Hatzis, 2014, Enhancing reproducibility in cancer drug screening: how do we move forward?, Cancer Res, 74, 4016, 10.1158/0008-5472.CAN-14-0725 · DOI · Paper page
- Hebenstreit, 2012, Methods, challenges and potentials of single Cell RNA-seq, Biology, 1, 658, 10.3390/biology1030658 · DOI
- Marguerat, 2009, RNA-seq: from technology to biology, Cell Mol Life Sci, 67, 569, 10.1007/s00018-009-0180-6 · DOI · Paper page
- Szyf, 2009, Epigenetics, DNA methylation, and chromatin modifying drugs, Annu Rev Pharmacol Toxicol, 49, 243, 10.1146/annurev-pharmtox-061008-103102 · DOI · Paper page
Cited by
Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
Computational/in silico methods in drug target and lead prediction
Agamah, F. E., Mazandu, G. K., Hassan, R., Bope, C. D., Thomford, N. E., Ghansah, A., & Chimusa, E. R. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz103 · Cited by 328
A review of connectivity map and computational approaches in pharmacogenomics
Musa, A., Ghoraie, L. S., Zhang, S.-D., Galzko, G., Yli-Harja, O., Dehmer, M., Haibe-Kains, B., & Emmert-Streib, F. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbw112 · Cited by 260
Self-citationTargeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
An introduction and overview of machine learning in neurosurgical care
Senders, J. T., Zaki, M. M., Karhade, A. V., Chang, B., Gormley, W. B., Broekman, M. L., Smith, T. R., & Arnaout, O. (2018) · Acta Neurochirurgica · doi:10.1007/s00701-017-3385-8 · Cited by 178
Metadata
- Authors
- Madani Tonekaboni, S. A., Soltan Ghoraie, L., Manem, V. S. K., & Haibe-Kains, B.
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-11-15
- Volume
- 19
- Issue
- 2
- Pages
- 263-276
- ISSN
- 1467-5463 (ISSN-L)
- 1477-4054
- OpenAlex
- W2551072359
- Cited by
- 115
- References
- 29
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- Canadian Cancer Society Research Institute (#703886)
- National Institutes of Health (#236136)
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.